TrialArthritis research & therapy2021

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.

Roy M Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.